Who is affected by this change?

This affects Independence Blue Cross Neurology, Pediatrics providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Mar 4, 2026.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.086d, Nusinersen (Spinraza®)

Independence Blue Cross·Neurology, Pediatrics·Pharmacy

Effective date

Mar 4, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.086d for Nusinersen (Spinraza®) has been reissued and will take effect March 4, 2026. This is a pharmacy policy update that may affect coverage criteria, prior authorization requirements, or billing procedures for this spinal muscular atrophy treatment.

Action Required

Action needed

By March 4, 2026: Review updated MA08.086d policy for Nusinersen (Spinraza®) at the provided URL to identify specific changes to coverage criteria, prior authorization requirements, or billing procedures. Update billing protocols and staff training accordingly for Medicare Advantage plans.

Related policy hubs

Independence Blue Cross policies Neurology Pediatrics